Shares of Coloplast A/S (OTCMKTS:CLPBY – Get Rating) have earned a consensus rating of “Hold” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $1,038.00.
A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of Coloplast A/S from 1,014.00 to 980.00 and set a “neutral” rating on the stock in a research report on Tuesday. DNB Markets upgraded shares of Coloplast A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, January 26th.
Shares of CLPBY opened at $11.83 on Friday. The firm has a market cap of $25.55 billion, a PE ratio of 39.43 and a beta of 0.28. The firm’s 50 day moving average price is $14.37 and its 200 day moving average price is $15.41. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.90 and a current ratio of 1.29. Coloplast A/S has a twelve month low of $11.71 and a twelve month high of $18.90.
About Coloplast A/S (Get Rating)
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
- Get a free copy of the StockNews.com research report on Coloplast A/S (CLPBY)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.